Pharmaceutical company Mylan N.V. (NASDAQ:MYL) said on Tuesday that it has received tentative approval in the US for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets in 50 mg/200 mg/25 mg.
This approval was awarded by the US Food and Drug Administration (FDA) under the US President's Emergency Plan.
Mylan said this is the first tentative approval of Tenofovir Alafenamide and comes just two years after the US FDA approval of Descovy. The combination of these agents is currently included as a "Recommended Initial Regimen for Most People with HIV" in the HIV guidelines of the U S Department of Health and Human Services.
Effective immediately, the antiretroviral (ARV) will be launched in developing countries as a first-line regimen for people being treated for HIV/AIDS.
According to the company, the ARV is a once-daily, fixed-dose combination of Dolutegravir, Emtricitabine and Tenofovir Alafenamide, the individual components that make up ViiV Healthcare's Tivicay and Gilead's Descovy. The tablet will be the smallest sized single-tablet regimen available for patients in the developing world. It will be offered in a 90-day package as well as a 30-day one, potentially allowing patients fewer trips to the clinics for a refill.
The company reportedly manufactures these products under licenses from the Medicines Patent Pool and Gilead Sciences, respectively.
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results